Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Monia Ezzalfani"'
Autor:
Jan Astermark, Cédric Hermans, Monia Ezzalfani, Alaeddine Sidhom, Sylvaine Barbier, Nana Kragh, Aletta Falk, Daniel Eriksson
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of life (QoL). Previous post hoc analyses of prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) have been published for adults and adolesc
Externí odkaz:
https://doaj.org/article/407ec340e812478f87288a3666d21e9c
Autor:
John Pasi, Cédric Hermans, Zalmai Hakimi, Jameel Nazir, Samuel Aballéa, Monia Ezzalfani, Francis Fatoye
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Pain, a common symptom of hemophilia, begins early in life primarily due to joint bleeding. Recurrent bleeding adversely affects patients’ pain-related physical functioning, which can negatively impact their quality of life (QoL). Objec
Externí odkaz:
https://doaj.org/article/31fb3c4a1fa54f139d3fb1287ecbe898
Autor:
Monia Ezzalfani, Raphaël Porcher, Alexia Savignoni, Suzette Delaloge, Thomas Filleron, Mathieu Robain, David Pérol, ESME Group
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0255017 (2021)
PurposeObservational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders. In this work, we investigate the use
Externí odkaz:
https://doaj.org/article/f84c61bc31f24e18be5b443d6772f547
Autor:
Monia Ezzalfani
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0224940 (2019)
BackgroundIn oncology, the aim of dose-finding phase I studies is to find the maximum tolerated dose for further studies. The use of combinations of two or more agents is increasing. Several dose-finding designs have been proposed for this situation.
Externí odkaz:
https://doaj.org/article/88fe893faf764a2da9ae24e2ecd59e9e
Autor:
Maya Gutierrez, Isabelle Turbiez, David Ternant, Claire Bonneau, Olivier Le Tilly, Céline Desvignes, Monia Ezzalfani, Florence Oberkampf, Nicolas Azzopardi, Gilles Paintaud
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:210-219
Intravenous administration of monoclonal antibodies leads to low concentrations in the central nervous system, which is a serious concern in neuro-oncology, especially in leptomeningeal carcinomatosis of HER2-overexpressing breast cancer. Case report
Autor:
Jan Astermark, Cédric Hermans, Elena Santagostino, Samuel Aballéa, Monia Ezzalfani, Jameel Nazir, Zalmai Hakimi
Publikováno v:
Haemophilia, Vol. 28, no. 1, p. 18-26 (2022)
INTRODUCTION: Recurrent bleeding in severe haemophilia B causes painful hemarthroses and reduces capacity for physical activity. Recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis results in low annualised bleeding rates, with the potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266435102020f27a60e0a1be6fcf2605
https://hdl.handle.net/2078.1/261489
https://hdl.handle.net/2078.1/261489
Autor:
John Pasi, Cédric Hermans, Zalmai Hakimi, Jameel Nazir, Samuel Aballéa, Monia Ezzalfani, Francis Fatoye
Publikováno v:
Therapeutic advances in hematology, Vol. 13, no. 1, p. [1-9] (2022)
Background: Pain, a common symptom of hemophilia, begins early in life primarily due to joint bleeding. Recurrent bleeding adversely affects patients’ pain-related physical functioning, which can negatively impact their quality of life (QoL). Objec
Autor:
Stephanie Vairy, Claire Berger, Isabelle Aerts, Karsten Nysom, Angelo Paci, Francois M Petit, Marie-Cécile Le Deley, Anne-Isabelle Bertozzi, Angela Di Giannatale, Raquel Hladun-Alvaro, Aurelie Chevance, P. Leblond, Birgit Geoerger, Francisco Bautista, Dominique Vidaud, Gilles Vassal, Anne Pagnier, Emilie De Carli, Gwénaël Le Teuff, Fanny Fouyssac, Sandra Canale, Jacques Grill, Monia Ezzalfani, Frédéric Millot, Vianney Poinsignon
Publikováno v:
Neuro-oncology Advances
Background New rescue regimens are needed for pediatric refractory/recurrent low-grade glioma. Nilotinib is a tyrosine kinase inhibitor that has potential synergistic effects with vinblastine on angiogenesis, tumor cell growth, and immunomodulation.
Publikováno v:
Statistics in Medicine. 36:67-80
Phase I oncology trials are designed to identify a safe dose with an acceptable toxicity profile. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle, although patients continue to re
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Autor:
Laurence Vanlemmens, Marc Debled, Christian Cailliot, Elisa Gobbini, Thomas Bachelot, Monia Ezzalfani, Christelle Jouannaud, Suzette Delaloge, Magali Lacroix-Triki, Anne Patsouris, Thierry Petit, Simone Mathoulin-Pélissier, Veronique Lorgis, William Jacot, Marie Ange Mouret-Reynier, Mathieu Robain, C. Lefeuvre-Plesse, Florence Dalenc, Audrey Lardy Cleaud, Etienne Brain, Christelle Levy, David Pérol, C. Courtinard, Véronique Diéras, Marianne Leheurteur, Lionel Uwer, Anthony Gonçalves, Jean Marc Ferrero
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩
European Journal of Cancer, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩
European Journal of Cancer, Elsevier, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩
European Journal of Cancer, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩
Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the yea